Procurement Summary
Country: USA
Summary: Notice of Contract Award - Orexo US, Inc.
Deadline: 24 Sep 2025
Other Information
Notice Type: Tender
TOT Ref.No.: 127176706
Document Ref. No.: BARDA-BAA-OrexoNotice
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_details
Login to see detailsTender Details
Description
Award Notice for Orexo US, Inc. (Contract 75A50125C00010). Clinical development of Ox390 (atipamezole) as an α2 agonist reversal agent for human use to counteract the sedative effects of xylazine, medetomidine, and other α2 agonists that are increasingly found in combination with IMF.
Active Contract Opportunity
Notice ID : BARDA-BAA-OrexoNotice
Related Notice
Department/Ind. Agency : HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier : OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
Office: BARDA - ASPR / DAAPPO / BARDA DCMA
General Information
Contract Opportunity Type: Special Notice (Original)
Original Published Date: Sep 26, 2025 01:05 pm EDT
Original Response Date: Sep 24, 2025 05:00 pm EDT
Inactive Policy: 15 days after response date
Original Inactive Date: Oct 09, 2025
Initiative: None
Classification
Original Set Aside: No Set aside used
Product Service Code: AN13 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; ExPERIMENTAL DEVELOPMENT
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Place of Performance: Morristown, NJ 07960 USA
Documents
Tender Notice
SAM-Post-Award-Notification-Orexo.pdf